藥明生物(02269.HK)美國首個研究服務中心開業
藥明生物(02269.HK)宣布,旗下位於美國波士頓研究服務中心正式開業,成為公司全球第三個研究服務中心,以及在美國的首個研究服務中心,預料將為不同規模的客戶,特別是初創公司,提供早期發現服務。
首席執行官陳智勝表示,透過新開幕的波士頓研究服務中心,公司將為客戶提供更近距離的早期發現服務,為創新創業注入強大動能,希望打造業界領先、全面全面的能力和技術平台,提供一體化和模組化的解決方案,讓任何客戶都能加速生物藥創新,惠及更多全球病患。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.